MVM invests in MDxHealth SA

In May 2020, MVM closed a growth investment in MDxHealth SA, a company that markets proprietary, differentiated tests that optimize the care of patients with prostate cancer. MDxHealth’s two commercial tests, SelectMDx and ConfirmMDx, improve patient care and reduce costs by helping clinicians avoid unnecessary prostate biopsies.

MDxHealth will appoint Eric Bednarski as director of the company and Kyle Dempsey will join as a board observer.